Jiangsu Hengrui Medicine

Jiangsu Hengrui Pharmaceuticals Company Ltd., also known as Jiangsu Hengrui, is a Chinese pharmaceutical firm that makes and distributes drug packaging materials, cancer-treating antineoplastics, cardiovascular medication, painkillers, antibiotics, and other related items. It is China's largest publicly traded pharmaceutical corporation.

Jiangsu Hengrui Pharmaceuticals, formerly known as Lianyungang Pharmaceutical Factory, was founded in 1970. Its current headquarters are in Lianyungang, Jiangsu, and it was founded in 1977. In 2000, the firm went public on the Shanghai Stock Exchange, and it now has offices in China, the United States, Germany, Switzerland, Japan, and Australia.

Jiangsu Hengrui Pharmaceuticals will open research and development offices in Princeton, New Jersey, and Basel, Switzerland in 2020. The discovery research and development units are also housed at Hengrui Europe Therapeutics AG in Switzerland. Their primary interests are protein engineering and the mRNA technology platform.

Jiangsu Hengrui Pharmaceuticals has been conducting clinical trials on anti-cancer medications such as:

• An anti-PD-1 immune checkpoint inhibitor camrelizumab for hepatocellular carcinoma;
• A nonsteroidal antiandrogen rezvilutamide for prostate cancer;
• A PARP inhibitor fluzoparib for solid cancers, especially prostate cancer;
• A VEGFR2 inhibitor apatinib as a combination therapy.

Trials were also conducted in the fields of metabolic illnesses (for example, type 2 diabetes), autoimmune diseases (in psoriasis, the interleukin-17 receptor blocker vanucizumab), HIV treatment, and analgesia.

Founded: 1997
Headquarters: Lianyungang, Jiangsu, China
Key people: Sun Piaoyang (chairman)

Website: https://www.hrs.com.cn/